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Epileptic encephalopathy (EE) refers to a clinically and genetically heterogeneous group of severe disorders characterized by seizures,
abnormal interictal electro-encephalogram, psychomotor delay, and/or cognitive deterioration. We ascertained two multiplex families
(including one consanguineous family) consistent with an autosomal-recessive inheritance pattern of EE. All seven affected individuals
developed subclinical seizures as early as the first day of life, severe epileptic disease, and profound developmental delay with no facial
dysmorphism. Given the similarity in clinical presentation in the two families, we hypothesized that the observed phenotype was due to
mutations in the same gene, and we performed exome sequencing in three affected individuals. Analysis of rare variants in genes consis-
tent with an autosomal-recessive mode of inheritance led to identification of mutations in SLC13A5, which encodes the cytoplasmic
sodium-dependent citrate carrier, notably expressed in neurons. Disease association was confirmed by cosegregation analysis in
additional family members. Screening of 68 additional unrelated individuals with early-onset epileptic encephalopathy for SLC13A5
mutations led to identification of one additional subject with compound heterozygous mutations of SLC13A5 and a similar clinical pre-
sentation as the index subjects. Mutations affected key residues for sodium binding, which is critical for citrate transport. These findings
underline the value of careful clinical characterization for genetic investigations in highly heterogeneous conditions such as EE and
further highlight the role of citrate metabolism in epilepsy.Early-onset epileptic encephalopathy (EOEE) is ahighlyhet-
erogeneous group of severe epileptic disorders characterized
by pharmacoresistant seizures and abnormal interictal elec-
troencephalogram (EEG) that leads to neurological impair-
ment, developmental delay, and high mortality rate.1–3
Given the extreme etiological heterogeneity of EOEE, clin-
ical, electro-clinical, and genetic classification are of consid-
erable importance for therapeutic management of affected
individuals, prognosis, and genetic counseling.4 Among
EOEE, a number of electro-clinical neonatal-onset epileptic
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The Adrome (MIM 308350), early myoclonic epilepsy (MIM
607208), and malignant migrating partial seizures (MIM
614959). Many forms of EOEE nonetheless remain difficult
to delineate based on clinical and EEG findings only, and
conventional metabolic and genetic screening remain
tedious and lowyield. This is particularly true for individuals
with EOEE and onset of seizures in the first day of life with
no evidence of neonatal suffering or environmental causes,
becausemutations inEOEE-associatedgeneshavebeenonly
rarely found in such individuals. Although systematic
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Figure 1. Pedigrees of the Three Families
with SLC13A5 Mutations
Individuals for whom exome sequencing
was performed are indicated by asterisks
(*). The subject with a homozygous
BCKDHBmutation is indicated by the sym-
bol {. Detection of the identified SLC13A5
variants was performed in all available
individuals. mut/mut and mut/ refer
to compound heterozygous and het-
erozygous carriers of SLC13A5 mutations,
respectively. / indicate individuals
for whom no SLC13A5 mutation was
identified.diagnostic yield, careful clinical and EEG description of
epileptic syndromes is needed for improved management
of affected individuals.5–7
We ascertained two families comprising seven affected
individuals with strikingly similar clinical presentations
of EOEE. The pedigrees (families 1 and 2, shown in Figure 1)
were highly suggestive of an autosomal-recessive mode of
inheritance. For all subjects, brain imaging (including
magnetic resonance imaging [MRI] and computerized to-
mography scanner [CT-scan]), infectious work-up in blood
as well as urine and cerebrospinal fluid (CSF), and meta-
bolic work-ups were not conclusive. In family 1, subject 1
(II-1 in Figure 1) was born after an unremarkable full-
term pregnancy. American Pediatric Gross Assessment
Record (APGAR) was 10/10 with eutocic delivery. Clinical
and neurological examinations were reported as unremark-
able at birth. At day 1, he experienced a multifocal status
epilepticus characterized by long-lasting focal seizures
alternately involving right and left temporo-occipital
areas. There was no evidence for a materno-fetal infection.
Seizures were subclinical (Table 1) albeit almost continuous
during the first days of life. Initial EEG revealed oscillating
delta-theta waves that increased in amplitude, lastingmore
than 2 min and restricted to the temporal and occipital
brain areas. Interictal EEG was low in amplitude, without
suppression bursts. Overall, the recurrence of focal seizures
with almost no interictal period for several hours led to the
clinical diagnosis of neonatal multifocal status epilepticus.
After the age of 2 months, epileptic activity became rarer
and responded well to antiepileptic drugs, with persistence
of some seizures triggered by fever. Clinical evolution was
characterized by a major psychomotor delay with no eye
contact and global hypotonia without pyramidal syn-
drome. No facial dysmorphism was noticed, except for
widely spaced teeth. Growth, including occipito-frontal
circumference (OFC), was normal. Subject 2 (II-3 in
Figure 1) was born after an uneventful pregnancy at
35 weeks of gestation, with birth parameters in normal114 The American Journal of Human Genetics 95, 113–120, July 3, 2014range. Delivery was complicated by
inhalation of meconial amniotic fluid
requiring an initial hospitalization in
intensive care unit for assisted ventila-
tion. APGAR was 3/5/7. At 5 days oflife, she presented with a status epilepticus, controlled by
the association of three antiepileptic drugs. Status epilepti-
cus was well tolerated despite a succession of prolonged,
focal seizures with very short interictal periods. Epileptic
signs included chewing movements and modification of
breath occurring several seconds after the beginning of
the EEG discharge. EEG showed rhythmic theta-delta
focal discharges originating alternatively from both hemi-
spheres, mostly in the left and right temporal regions
(a representative EEG is shown in Figure 2). No truly
migrating seizures could be observed. Brain MRI showed
no lesions suggestive of a perinatal insult. At 2 years and
4 months of age, clinical examination showed axial hypo-
tonia without peripheral hypertonia or pyramidal syn-
drome. Ocular contact was good with smiling response.
Head was controlled but sitting was not acquired. Volun-
tary grasping was absent. Growth and OFC were normal.
Although subject 2 showed a better psychomotor develop-
ment than subject 1 indicating some degree of intrafami-
lial phenotypic variability, both affected individuals from
family 1 display a severe EE with absent speech and no
sitting position.
Family 2 is an Algerian family harboring two consan-
guinity loops. In the first nuclear family, three out of five
children developed a severe EE. In all children, antenatal
period and delivery were unremarkable. Subject 3 (V-1 in
Figure 1) presented polymorphic seizures beginning in
the first day of life and associating cyanosis, hemibody
abnormal movements, upper limbs clonus, and abnormal
ocular movements. The first status epilepticus was reported
at 1 month of life and required a therapeutic association of
three antiepileptic drugs to stabilize a monthly occurrence
of seizures. Psychomotor milestones were not acquired,
with poor eye contact and no sitting at 5 years of age.
Fewer epileptic manifestations were reported over follow-
up. No facial dysmorphism was noticed except for widely
spaced teeth, also observed in family 1. EEGs were asym-
metrically slower on right side. A mild perceptive deafness
Table 1. Clinical Hallmark of the Epileptic Disease and Psychomotor Acquisitions of the Eight Reported Subjects
Clinical Hallmarks
Family 1 Family 2 Family 3
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7 Subject 8
Epilepsia type EOEE EOEE EOEE EOEE EOEE EOEE EOEE EOEE
Age at first seizures 1 day 5 days 1 day 1 day 1 day 1 week 1 week 1 day
Age at first status epilepticus 1 day 5 days 1 month none 1 day NA NA 1 day
Seizure type subclinical subclinical polymorphic subclinical subclinical NA subclinical subclinical
Psychomotor
acquisitions
profound
delay
severe
delay
profound
delay
severe
delay
severe
delay
profound
delay
profound
delay
profound
delay
Eye contact no yes poor yes yes yes yes yes
Head control no yes yes yes yes yes yes yes
Sitting acquired no no no yes no no no yes
Speech none none none none none none none none
Abbreviations are as follows: EOEE, early onset epileptic encephalopathy; NA, not available.was reported. Subject 4 (V-2 in Figure 1) was born after an
uneventful pregnancy. A perinatal suffering was suspected
and required resuscitation. He presented seizures at 8 hr of
life. A neonatal subdural hematoma was reported. Given
the family history, antiepileptic drugs were introduced
early. Psychomotor acquisitions were markedly delayed.
At 5 years of age, he was able to say several words. He
kept presenting weekly seizures. Neurological examination
showed axial hypotonia and peripheral hypertonia with
brisk tendon reflexes. No facial dysmorphism was noticed,
except for hypodontia. Growth parameters including OFC
were in normal range. Subject 5 (V-5 in Figure 1) was born
at full term of an uneventful pregnancy. Birth measure-
ments and APGAR were normal. He presented a status epi-
lepticus resistant to standard therapeutics at 20 hr of life. A
maple syrup disease (MIM 248600) was diagnosed on plas-
matic amino acid chromatographs, which was confirmed
by the identification of a homozygous truncating muta-
tion (c.799C>T [p.Gln267*]) in BCKDHB (RefSeq accession
number NM_183050.2, MIM 248611). Segregation anal-
ysis in other family members showed that subjects 3 and
4 were heterozygous carriers. Dietary care biochemically
controlled perfectly the maple syrup disease, with normal
chromatography at follow-up. Evolution was marked by
a severe psychomotor delay. Walk had not been acquired
by the age of 3 years. Epilepsy was very active in the first
months of age with almost continuous subclinical seizures.
EEG showed almost continuous sequences of focal seizures
involving temporal and occipital regions of both hemi-
spheres alternatively, mostly the left one, with rhythmic,
large-amplitude spikes lasting several minutes. There was
no suppression burst. After 1 month of age, EEG rapidly
improved, and a background activity was recorded and
found normal. After 3 months, some asymptomatic, short
generalized discharges of spikes were recorded. Subjects 6
and 7 (V-6 and V-9 in Figure 1) presented a severe EE
with seizure onset in the first days of life. Subject 6 (V-6
in Figure 1) died at 11 years of age of unknown cause. Sub-The Aject 7 (V-9 in Figure 1) presents epileptic seizures at 5 years
of age.
We propose that the combination of clinical findings
observed in affected individuals from the two families
(summarized in Table 1, with additional clinical informa-
tion in Table S1 available online) define a distinctive
epileptic phenotype. Evidence supporting a genetic etiol-
ogy included (1) the context of familial forms of EE; (2)
brain imaging and clinical evolution, which did not sup-
port neonatal insult as the cause of the clinical presenta-
tion; and (3) the fact that neonatal suffering may be
both a consequence of, and a contributing factor to, the
observed epileptic disease. Clinical hallmarks comprise
nonmotor and pharmacoresistant seizures with onset in
the first days of life evolving to pharmacoresistant EE
in the first months, profound psychomotor delay, and
neonatal EEG showing a recurrent pattern of multifocal
long-lasting temporo-occipital seizures involving both
hemispheres.
We hypothesized that the observed clinical presentation
in the two families was due to mutations in the same gene
and performed exome sequencing in three affected indi-
viduals (II-1, II-3, and V-5 in Figure 1). Written, informed
consent was obtained from all subjects, legal representa-
tives, and relatives before enrollment in the study. The
ethics committee at participating institutions approved
the research protocol. Genomic DNA was extracted from
blood via standard procedures. Whole-exome capture
and sequencing were performed at Integragen from 3 mg
of genomic DNA per individual using the SureSelect
Human All Exon V5 kit (Agilent). The resulting libraries
were sequenced on a HiSeq 2000 (Illumina) according
to the manufacturer’s recommendations for paired-end
76 bp reads. More than 4.8 gigabases of mappable se-
quences per individual were generated, resulting in a depth
of coverage of at least ten reads for more than 93% of
RefSeq coding exons (Table S2). Reads were aligned to the
human genome reference sequence (GRCh37/hg19 buildmerican Journal of Human Genetics 95, 113–120, July 3, 2014 115
Figure 2. Subject 2: Epileptic Activity with Long-Lasting Multifocal Bilateral Seizures during the First Week of Life
(A) Schematic representation of the electrode placement according to the international standards in neonate (subject 2 at fifth day
of life).
(B) Longitudinal (lines 1–6) and transverse montage (lines 7–10) showing a typical seizure beginning in the right hemisphere, temporal
region (dotted line), lasting around 100 s and immediately followed by a seizure originating in the left hemisphere, temporal lobe (full
trace) beginning at around 100 s and lasting 130 s. Clinically, the discharge was not symptomatic initially, then the neonate displayed
chewing movements (20th s), discrete clonic jerks of the left limbs (50th s), and discrete clonic jerks of the right limbs (130th s).of UCSC Genome Browser) with the Burrows-Wheeler
Aligner (BWA, v.0.6.2), and potential duplicate paired-
end reads were marked with Picard v.1.77. The Genome
Analysis Toolkit (GATK) v.2.6-4 was used for base quality
score recalibration, indel realignment, and variant discov-
ery (both single-nucleotide variants and indels).8 Variants
were annotated with SeattleSeq SNP Annotation. Rare var-
iants were identified by focusing on protein-altering and
splice-site changes present at a frequency less than 1% in
dbSNP 138 and the NHLBI GO Exome Sequencing Project
and absent from 50 local exomes of unaffected individuals.
Candidate genes consistent with an autosomal-recessive
mode of inheritance were systematically identified based
on the presence of at least one rare homozygous or two het-
erozygous variants as described previously.9 This strategy
led to identification of a single gene mutated in all three
affected individuals (Table S3), namely SLC13A5 (MIM
608305; RefSeq NM_177550.3), which encodes the only
known neuronal cytoplasmic sodium-dependent citrate
carrier.10 Both affected individuals from family 1were com-
pound heterozygous for two SLC13A5 missense changes
(c.655G>A [p.Gly219Arg] and c.680C>T [p.Thr227Met])116 The American Journal of Human Genetics 95, 113–120, July 3, 20(Figure S1), and subject 5 from family 2 had a homozygous
SLC13A5 missense change (c.1463T>C [p.Leu488Pro])
(Figure S1; Table 2). Cosegregation analysis in all available
relatives by standard polymerase-chain-reaction (PCR)
protocols using custom intronic primers (Table S4) and
capillary sequencing confirmed the association of the
identified SLC13A5 mutations with EOEE in both families
(Figure 1).
We then screened SLC13A5 for mutations in 68 unre-
lated individuals with EOEE, including 61 subjects with
unclassified epilepsy and 7 subjects with suppression-burst
EEG patterns. Overall, 29 subjects had onset of seizures in
the first week of life combined with severe psychomotor
delay, and 15 out of these 29 individuals had been screened
for mutations in STXBP1 and KCNQ2, which had failed
to identify disease-associated variants. Coding regions
of SLC13A5 were amplified by standard PCR protocols
(primer sequences are listed in Table S4). For each individ-
ual, PCR products were pooled and libraries were prepared
with the Nextera XT DNA Sample Preparation kit (Illu-
mina). Generated libraries were sequenced on a MiSeq
instrument (Illumina) according to the manufacturer’s14
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The Arecommendations for paired-end 150 bp reads. Sequencing
data processing and variant identification were performed
as described above, except that PCR duplicates were not
marked. The average sequencing depth of SLC13A5 coding
exons (RefSeq) and splice junctions was 2,158-fold, with
100% of targeted bases covered by at least 10 reads in
all subjects. This experiment led to identification of one
additional subject with identical compound heterozy-
gous mutations as those found in family 1 (c.655G>A
[p.Gly219Arg] and c.680C>T [p.Thr227Met]; family 3 in
Figure 1). Single-nucleotide variants flanking the identified
mutations seem to argue against identity by descent and
support distinct mutational events in families 1 and 3, at
least for one of the two variants (Table S5).
In striking similarity with the clinical presentation of
affected individuals from families 1 and 2, this subject
developed subclinical seizures at 2 hr of life and presented
with a severe epileptic disease that evolved to a pharmacor-
esistant EE associated with major developmental delay
(Tables 1 and S1). Highly frequent focal seizures lasting
several days were initially noticed, followed by periods of
relative stability (with rare occasional seizures) alternating
with clusters of seizures occurring once or twice a year. No
seizures were recorded by video/EEG. Interictal EEGs were
well organized.
An additional heterozygous SLC13A5 variant (c.655G>A
[p.Gly219Arg]) was detected in another subject (family 4,
Table 2). Clinical presentation of this affected individual—
which comprised seizure onset at 1 month of age and mild
psychomotor delay associated with autism spectrum disor-
der—showed no similarity with the phenotype of affected
individuals with recessive SLC13A5 mutations. In the
absence of a second detectable mutation of SLC13A5 in
this individual and given the fact that heterozygous carriers
of the p.Gly219Arg mutation in families 1 and 3 are unaf-
fected, we conclude that this mutation alone is unlikely to
cause the observed phenotype. No other coding variants
were identified in the remaining 66 individuals tested.
Nucleotide-level conservation and impact of amino acid
substitutions were assessed by the Genomic Evolutionary
Rate Profiling (GERP),11 Grantham matrix,12 Polyphen-2
(using the HumVar-trained model),13 and Combined
Annotation-Dependent Depletion (CADD)14 scores. All
mutation sites were found to affect highly conserved
nucleotides and amino acids and were predicted as likely
deleterious (Table 2, Figure S2). None of the three muta-
tions were reported in the NHLBI GO Exome Sequencing
Project. However, one of the mutations was reported in
dbSNP v.134, with neither frequency nor validation data
(Table 2).
SLC13A5 encodes a highly conserved homodimeric cyto-
plasmic sodium-dependent citrate carrier composed of 11
transmembrane domains. Functional and structural work
on VcINDY—the bacterial orthologous of SLC13A5—
showed that sodium binding is required for citrate transport
and identified two sodium binding domains:15 one at resi-
due VcINDY-Gly199 (HsSLC13A5-Gly226) and the secondmerican Journal of Human Genetics 95, 113–120, July 3, 2014 117
Figure 3. In Silico Prediction of the Impact of SLC13A5 Muta-
tions on Sodium Binding
Left panel represents 3D model of VcINDY, SLC13A5 bacterial or-
tholog (PDB 4F35). Citrate molecule (yellow) and the first sodium-
binding site (green) are shown. Right panels are 6 A˚ zoomed-in
focuses of both wild-type and mutated residues. Protein structure
data were loaded in the Swiss-PDB viewer and mutated residues
introduced, with the most probable rotamer selected. Hydrogen
bonds were computed by standard parameters.one between residues VcINDY-Glu374 and VcINDY-
Cys413 (HsSLC13A5-Glu475 and HsSLC13A5-Phe500,
respectively). Intracellular citrate transport was shown to
be dramatically reduced when these latter two residues
are mutated.16,17 In addition, systematic mutagenesis of
SLC13A5carboxy-terminal regiondemonstrated the confor-
mational role of the highly conserved residue HsSLC13A5-
Leu488 (rbSLC13A5-Leu502) for dicarboxylic acid binding
and transport.18,19 Strikingly, all three mutations sites re-
ported here affect either the first sodium-binding site
(p.Gly219Arg and p.Thr227Met in families 1 and 3) or the
second one (p.Leu488Pro in family 2). This hypothesis is
further supported by in silico predictions of the impact of
p.Gly219Arg and p.Thr227Met mutations on the first so-
dium binding site, which show a marked disruption of
hydrogen bonds (Figure 3). We can therefore speculate that
these mutations may affect the ability of SLC13A5 to trans-
port citrate across the plasma membrane to the cytosol by
disrupting its ability to bind sodium.
Citrate plays a pivotal role for cellular metabolism and
neurotransmitter biogenesis such as glutamate in the brain.
Intracellular citrate metabolism is essential for tri-carbox-
ylic acids synthesis and mitochondrial energetic balance,
and the rate of fatty-acid synthesis depends on the concen-
tration of citrate in the cytosol, which is mainly controlled
by SLC13A5.20 Disruption of citrate metabolism and trans-
port were previously associated with epilepsy. For instance,
mutations in the mitochondrial di- and tri-carboxylic acid
transporters SLC25A1 (MIM 190315) and SLC25A22 (MIM
609302) cause hydroxyglutaric aciduria (MIM 615182)
and early infantile epileptic encephalopathy-3 (MIM
609304), respectively.21,22 Conversely, increased citrate
synthetase activity in rat brain homogenates was observed
after convulsing doses of 3-mercaptopropionic acid, thus
indicating that high intracellular citrate concentrations
may be an endogenous anticonvulsive mechanism.23
Finally, although Slc13a5-knockout mice have no signs of
developmental or neurological abnormalities, knockout118 The American Journal of Human Genetics 95, 113–120, July 3, 20mice of two of the five SLC13 family members develop
seizures.15,24,25
Neonatal epilepsies are highly heterogeneous in terms
of etiology and electro-clinical features. Approximately
20% of neonatal-onset EE of genetic origin are caused by
mutations in three major genes, namely STXBP126 (MIM
602926), KCNQ227 (MIM 602235), and KCNT128 (MIM
608167). Mutations in these genes are mostly associated
withmalignantmigrating partial seizure28 or with suppres-
sion-burst pattern.29,30 Here, we describe a form of epilepsy
associated with SLC13A5 mutations and presenting with
status epilepticus in the first days of life, EEG patterns
showing bilateral, multifocal, long-lasting nonmigrat-
ing seizures and severe neurological evolution despite a
decrease of seizure frequency concomitant with a rapid
improvement of the EEG background activity. Screening a
cohort of 29 subjects with seizure onset in the first week
of life combined with severe psychomotor delay identified
one additional individual with SLC13A5 mutations and a
very similar clinical and EEG presentation as the two index
families. Given the rarity of epileptic seizures with onset
in the first day of life and the recognizable EEG pattern
described here, SLC13A5 may be considered as an addi-
tional gene to be screened in individuals with seizures in
the first day of life for molecular diagnosis purposes.
To conclude, we propose the existence of an auto-
somal-recessive and clinically distinctive EE associated
with SLC13A5 mutations, whose main clinical features
comprise seizure onset in the first days of life, subclinical
epileptic status, and recognizable EEG patterns with bilat-
eral, multifocal status epilepticus. Altogether, these find-
ings underline the value of careful clinical characterization
for genetic investigations in highly heterogeneous condi-
tions such as EE, might have direct implications for the
clinical management of this subset of individuals with
seizure onset in the first week of life, and further highlight
the role of citrate metabolism in epilepsy. Finally, these
findings may ultimately open therapeutic perspectives
aimed at increasing intracellular citrate concentration,
such as ketogenic diet or triheptanoin treatment.31,32Supplemental Data
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